Source link : https://www.newshealth.biz/health-news/impact-of-recombinant-replacement-therapy-detailed-in-genetic-clotting-disorder/
A recombinant replacement for the ADAMTS13 protein (Adzynma) missing in congenital thrombotic thrombocytopenic purpura (TTP) restored levels and reduced acute TTP events, according to interim trial data that led to FDA approval. For the primary endpoint, no acute TTP events occurred among patients getting prophylactic ADAMTS13 compared with one case on standard therapy with plasma-derived […]
Author : News Health
Publish date : 2024-05-01 21:00:00
Copyright for syndicated content belongs to the linked Source.
in Health